advertisement

WGA Rescources

Abstract #45990 Published in IGR 13-2

The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients

Sorkhabi R; Alipanahi R; Eftakhari-Milani A; Ghojazadeh L
Journal of Glaucoma 2011; 20: 240-243


Purpose: To evaluate the effect of diclofenac sodium 0.1% on reducing intraocular pressure (IOP) by latanoprost 0.005% in glaucoma patients. Patients And Methods: Twenty-two patients with bilateral primary open angle glaucoma were enrolled in this study. All patients had been given only latanoprost for at least 4 weeks. Topical diclofenac sodium was additionally applied to one eye (dicloptin group), whereas hydroxypropyl methyl cellulose was administered into the other eye (control group); both 4 times a day for 2 weeks. IOP measurement was performed before and 2 weeks after the administrations, and also 2 weeks after discontinuing additional ophthalmic solutions. Results: No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the dicloptin group and the control group (P=0.47). Additional administration of diclofenac sodium increased mean IOP from 15.73(plus or minus)1.75 to 17.32(plus or minus)2.23 mm Hg (P=0.01). This increase was reversed 2 weeks after discontinuing additional solutions (P=0.80); however, no significant difference in mean IOP was observed in the control group after administration and after discontinuing the additional medication (P=0.94 and 0.84, respectively). Conclusions: Topical diclofenac sodium may interfere with the IOP lowering effect of latanoprost in glaucoma patients; therefore this interference should be noted in coadministration of these drugs.

R. Sorkhabi. Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Abbasi Street, Tabriz 51664, Iran. Email: Sorkhabi_r@yahoo.com


Classification:

11.4 Prostaglandins (Part of: 11 Medical treatment)
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)



Issue 13-2

Change Issue


advertisement

Oculus